ArticleRheumatology (Oxford, England)2013
Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.
Article in Rheumatology (Oxford, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Polychondritis and Arthritis in a Patient with Coexisting Alkaptonuria and Psoriasis Vulgaris.Internal medicine (Tokyo, Japan) · 2026Article
- An in vitro cell model for exploring inflammatory and amyloidogenic events in alkaptonuria.Journal of cellular physiology · 2024Article
- Review
- Alkaptonuria.Nature reviews. Disease primers · 2024Review
- Increased prevalence of Parkinson's disease in alkaptonuria.JIMD reports · 2023Article
- Untargeted NMR Metabolomics Reveals Alternative Biomarkers and Pathways in Alkaptonuria.International journal of molecular sciences · 2022Article
- Article
- Immunomodulatory and biological properties of helminth-derived small molecules: Potential applications in diagnostics and therapeutics.Frontiers in parasitology · 2022Review
- A molecular spectroscopy approach for the investigation of early phase ochronotic pigment development in Alkaptonuria.Scientific reports · 2021Article
- A Mimic of Ankylosing Spondylitis, Ochronosis: Case Report and Review of the Literature.Current allergy and asthma reports · 2021Review
- Towards a Precision Medicine Approach Based on Machine Learning for Tailoring Medical Treatment in Alkaptonuria.International journal of molecular sciences · 2021Article
- Metabolomes and Lipidomes of the Infective Stages of the Gastrointestinal nematodes,Metabolites · 2020Article
- Angiogenesis in alkaptonuria.Journal of inherited metabolic disease · 2016Article
- A role for interleukins in ochronosis in a chondrocyte in vitro model of alkaptonuria.Clinical rheumatology · 2016Article
- The Distribution of Ochronosis in Osteoarthritic Articular Cartilage in a Knee.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2016Article
- Importance of serum amyloid-A in Behçet's disease.Clinical rheumatology · 2016Article
- Amyloidosis in alkaptonuria.Journal of inherited metabolic disease · 2015Review
- Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria.Journal of inherited metabolic disease · 2015Review
- Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria.Journal of inherited metabolic disease · 2015Article
- Chondroptosis in alkaptonuric cartilage.Journal of cellular physiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
objectiveAlkaptonuria (AKU) is an ultra-rare autosomal recessive disease that currently lacks an appropriate therapy. Recently we provided experimental evidence that AKU is a secondary serum amyloid A (SAA)-based amyloidosis. The aim of the present work was to evaluate the use of antioxidants to inhibit SAA amyloid and pro-inflammatory cytokine release in AKU.
methodsWe adopted a human chondrocytic cell AKU model to evaluate the anti-amyloid capacity of a set of antioxidants that had previously been shown to counteract ochronosis in a serum AKU model. Amyloid presence was evaluated by Congo red staining. Homogentisic acid-induced SAA production and pro-inflammatory cytokine release (overexpressed in AKU patients) were evaluated by ELISA and multiplex systems, respectively. Lipid peroxidation was evaluated by means of a fluorescence-based assay.
resultsOur AKU model allowed us to prove the efficacy of ascorbic acid combined with N-acetylcysteine, taurine, phytic acid and lipoic acid in significantly inhibiting SAA production, pro-inflammatory cytokine release and membrane lipid peroxidation.
conclusionAll the tested antioxidant compounds were able to reduce the production of amyloid and may be the basis for establishing new therapies for AKU amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.